Peptides DB
Research-centric peptide and protocol reference hub

Leuprorelin record · updated 9h ago

Healing & recoveryGrade A · human clinicalResearch use only
All 34 studiesJump to the evidenceCompare
What is Leuprorelin used for?

Leuprorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH) that functions primarily as a GnRH agonist. Its mechanism of action involves the downregulation of gonadotropin secretion from the pituitary gland, leading to decreased levels of sex hormones such as testosterone and estrogen. This property makes leuprorelin particularly useful in the management of hormone-sensitive conditions, including prostate cancer, endometriosis, and precocious puberty.

How it works: GnRH agonist

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection

Development stage

where Leuprorelin sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 111 registered trials. It describes the research record, not a recommendation.

Identity
NameLeuprorelin
Chain length—
Molecular weight1,209.4 Da
FormulaC59H84N16O12
Structure typeNot established
ClassInflammation
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 657181. No verified residue count for this compound.

Pharmacology
MechanismGnRH agonist
RouteSubcutaneous injection
Half-life~3 hours
Time to peak1–2 hours
Duration1 month
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Nov 5, 2026. How this works →
Research stats
Total studies34
Human / animal / cellular22 / 6 / 0
Highest trial phasePhase 4
Years covered2021–2026
Latest study1d ago
Publication history
20212026
Research funding
141 NIH projects · $32.2M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports1,138
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

34 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Leuprorelin Suppresses Angiogenesis and Malignant Progression in Endometrial Cancer via Downregulation of the ELAVL1/VEGFA Axis.
FindingNot reported in abstract.
Animal2026Full text read0.70
Leuprorelin Suppresses Angiogenesis and Malignant Progression in Endometrial Cancer via Downregulation of the ELAVL1/VEGFA Axis.
FindingNot reported in abstract.
Animal2026Full text read0.70
Gene Therapy for Metastatic Castration-Resistant Prostate Cancer Using the JC Polyomavirus (JCPyV) Virus-Like Particles as a Gene Delivery Vector.
FindingNo significant differences in survival were observed among the MOCK, ENZ/LEU, and PSAtk-VLP/GCV groups (log-rank test, p = 0.7351).
Animal2026Full text read0.80
Effects of the GnRH agonist leuprorelin on liver volume in premenopausal women with severe polycystic liver disease.
FindingMedian liver growth rate 4.04 [-4.62 to 6.84] %/year in leuprorelin group vs. 11.0 [0.70-13.2] %/year in standard care group, p=0.15.
Human2026Full text read0.80
Myomatous erythrocytosis syndrome associated with an 8-kg uterine leiomyoma: a case report of diagnostic evaluation and perioperative management.
FindingHemoglobin was 20.1 g/dL at presentation, reduced to 11.4 g/dL at one-month follow-up.
Human2026Full text read0.80
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
TakeawayNot reported in abstract.
Human2026Title only0.10
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.
TakeawayNot reported in abstract.
—2026Title only0.10
Linzagolix versus leuprorelin in Japanese women with uterine leiomyomas: a phase 3, randomized, active-controlled, non-inferiority trial.
Finding89.9% of patients in the linzagolix group achieved a total PBAC score <10 from Weeks 6 to 12, 95% CI 83.7, 94.4.
Human2026Full text read0.90
Meningioma enlargement associated with luteinizing hormone-releasing hormone agonist therapy: two cases and supporting in vitro evidence.
FindingNot reported in abstract.
Human2023Full text read0.70
H&E to recurrence score: A step forward, but not yet a substitute for genomic testing.
FindingAUC of 0.898 for identifying recurrence score ≥26.
review2026Full text read0.80
Diagnosis of metastatic prostate cancer by supraclavicular lymph node excision in a patient with persistent macroscopic hematuria: A case report.
TakeawayConventional diagnostic methods may miss metastatic prostate cancer; comprehensive approaches, including advanced imaging, are crucial.
Human2026Full text read0.70
Peptide Therapeutics for Solid Tumors: Functional Classes, AI-Enhanced Discovery and Clinical Advances.
TakeawayPeptide therapeutics show potential in treating solid tumors, with AI enhancing their design and discovery.
review2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Leuprorelin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Leuprorelin is discussed should be drawn from it.